ArticleMicrobial cell factories2026
Model-driven exploration of lactose and galactose metabolism via an oxidoreductive pathway in Sungouiella intermedia for cell factory applications.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConverting industrial side streams into value-added chemicals using microbial cell factories is of increasing interest, as such processes offer sustainable solutions to reduce waste and production costs. However, developing new, efficient non-model cell factories for precision fermentation remains challenging due to limited knowledge about their metabolic capabilities.
resultsHere, we investigate the lactose and galactose metabolism of the understudied yeast Sungouiella intermedia (formerly Candida intermedia), using knowledge-matching of high-quality genome-scale metabolic model (GEM) with extensive experimental analysis, and determine its potential as a future cell factory on lactose-rich industrial side-streams. We show that this yeast possesses the conserved Leloir pathway as well as an oxidoreductive route for galactose catabolism. Model simulations and experimental data from continuous and batch bioreactors, transcriptomics, and metabolite analysis indicate that while the Leloir pathway dominates galactose metabolism in S. intermedia, the oxidoreductive pathway is employed in a condition-dependent manner. The yeast produces galactitol as a carbon overflow metabolite, facilitating redox cofactor balance during both lactose and galactose growth. Furthermore, the new metabolic insights facilitated the development of an improved bioprocess design, where an engineered S. intermedia strain could achieve galactitol yields of > 90% of the theoretical maximum using the industrial side-stream cheese whey permeate as feedstock. Additional strain engineering resulted in galactitol-to-tagatose conversion, proving the versatility of the future production host.
conclusionsOverall, this work sheds new light on the intrinsic interplay between parallel metabolic pathways that shape the lactose and galactose catabolism in S. intermedia. It also demonstrates how a GEM combined with experimental analysis can work in synergy to fast-forward metabolic characterization and development of new, non-model yeast cell factories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.